Unmet Needs and Looking Ahead in Follicular Lymphoma
Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.
R/R FL: The Role of PI3K Inhibitors
A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.
Third-Line Therapy in Follicular Lymphoma
Sameh Gaballa, MD, considers therapeutic options in the third-line setting and beyond for patients who relapse.
Tazemetostat for Relapsed/Refractory Follicular Lymphoma
Sameh Gaballa, MD, discusses molecular testing in the third-line setting and beyond, as well as the mechanism of action of tazemetostat in the treatment of relapsed/refractory follicular lymphoma.
Considerations for Treatment Selection in R/R FL
An expert in follicular lymphoma highlights factors to consider when choosing therapy for first relapse and how this impacts later line treatment, as well as molecular testing and MRD.
Treatment Options in Relapsed/Refractory Follicular Lymphoma
Sameh Gaballa, MD, discusses patients who relapse after frontline treatment as well as prognostic and predictive factors for relapse.